Press releases

February 12, 2018 Invitae reports over 150% volume and over 170% revenue growth for 2017
- Annual test volume exceeds high end of guidance - - Robust test volume and revenue growth expected to continue in 2018 and beyond - - Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -   Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 . "Over the past year, we have made significant strategic investments that we believe uniquely position our company to deliver affordable, high-quality, comprehensive genetic information and empower individuals to do more with that information," commented Sean George , chief executive officer of Invitae . "Our continued triple-digit volume and revenue growth demonstrates the power of our approach. Our cost structure, scalability and reputation has made us the fastest-growing genetic information company in hereditary cancer, and we are now leveraging that
Read more
January 31, 2018 Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , chief executive officer of Invitae , will participate in two upcoming investor conferences being held in New York City . Sean George will present at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 10:00 a.m. Eastern / 7:00 a.m. Pacific. Additionally, Sean George will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:30 a.m. Eastern / 7:30 a.m. Pacific. The live webcasts of both conference presentations may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusions of the presentations and will be archived on the company's website. About Invitae Invitae Corporation's ( NYSE: NVTA ) mission is to bring comprehensive genetic information into mainstream
Read more
January 29, 2018 Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 1395729. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir@invitae.com . The live webcast of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the
Read more
January 8, 2018 Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018
- 127% increase in annual test volume exceeds high end of projected range - -136% increase in full-year 2017 revenue in line with guidance - - Anticipates continued, robust test volume and revenue growth in 2018 on strength of newly expanded business - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include: 127% year-over-year growth in volume for the base business, excluding acquisitions, to more than 134,000 samples accessioned compared to approximately 59,000 in 2016. The results exceeded the high end of the company's previously increased projected range of 120,000-130,000 samples. 136% growth in revenue in the base business to approximately $59 million, excluding acquisitions. Results were within the company's $55-$65 million revenue guidance.
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 6.48 +0.29 +4.68% Volume: 679,899 20 minute delay February 16, 2018

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com